Drugs / STP938
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06297525 | Aug 2024 → Dec 2026 expected | cancer | Step Pharma, SAS | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05463263 | Aug 2022 → Dec 2026 expected | B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma | Step Pharma, SAS | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06786234 | Jun 2025 → Jun 2028 expected | essential thrombocythemia | Step Pharma, SAS | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STP938 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05463263 ↗ |
| Known as | Dencatistat | “A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial” NCT06786234 ↗2“A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas” NCT05463263 ↗ “Study of STP938 (Dencatistat) in Advanced Solid Tumours” NCT06297525 ↗ |
| Action | Inhibit | “The drug STP938 is an inhibitor of an enzyme called cytidine triphosphate synthase 1 (CTPS1).” NCT05463263 ↗ |
| Modality | Small molecule | “Small molecule” NCT05463263 ↗ |
| Route | Oral | “STP938 will be given as a tablet.” NCT05463263 ↗ |
| Target | CTPS1 | “CTPS1 Inhibitor STP938” NCT06297525 ↗ |